Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Antaiwei granules (安泰微颗粒) is a Traditional Chinese Medicine (TCM) therapeutic developed by Tasly Pharmaceutical Group. It is classified as a Class 1.1 new TCM drug in China, indicating a novel formulation or clinical application. The drug is specifically indicated for the treatment of the common cold with a 'wind-cold' pattern, a TCM diagnostic category characterized by symptoms such as chills, fever, headache, and lack of sweating. It is currently undergoing Phase III clinical evaluation (e.g., trial CTR20233850) to assess its efficacy and safety in adult patients. The formulation is delivered as oral granules and aims to provide symptomatic relief through the combined pharmacological activities of its constituent herbal ingredients, which typically involve antipyretic and anti-inflammatory effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Antaiwei granules.